Progesterone receptor isoforms as a prognostic marker in human endometrial carcinoma
Progesterone receptor isoforms as a prognostic marker in human endometrial carcinoma
复制标题
DOI：
10.1111/j.1349-7006.2006.00332.x
复制
发表时间：
2006-12-01
期刊：
影响因子：
5.7
通讯作者：
Sasano, Hironobu
中科院分区：
文献类型：
--
作者：
Saito, Sumika;Ito, Kiyoshi;Sasano, Hironobu
特异性孕激素受体（PR）异构体（PRA和PRB）作为子宫内膜癌预测因素的可能作用尚不清楚。本研究旨在评估子宫内膜样子宫内膜癌患者瘤内PR异构体状态的临床意义。我们对103例子宫内膜样子宫内膜癌进行了免疫组化研究。我们将这些发现与患者的各种临床病理参数联系起来。在51/103（48.5%）和79/103（76.7%）的癌患者中分别检测到PRA和PRB的免疫反应性。实时逆转录-聚合酶链反应检测PRB免疫反应状态与PRB mRNA表达量呈显著正相关（P = 0.012）。组织学分级越高，PR亚型表达越低（PRA和PRB分别为P = 0.0001和P = 0.002）。一种或两种PR亚型阴性的病例与较短的无病生存期和总生存期显著相关。在所有9例死亡患者（100.0%）中检测到这两种PR亚型中的一种或两种不存在，而在同一时期生存的94例患者中仅检测到43例（45.7%）不存在这些免疫反应性。此外，多因素分析表明，缺乏PRA免疫反应性是患者无病生存的独立危险因素（P = 0.0258）。我们的研究结果表明，免疫组化检测PR异构体表达的缺失或缺失可能成为子宫内膜样子宫内膜癌患者预后的重要指标。
The possible role of specific progesterone receptor (PR) isoforms (PRA and PRB) as predictive factors in endometrial carcinoma is unclear. The present study was undertaken to evaluate the clinical significance of intratumoral PR isoform status in patients with endometrioid endometrial carcinoma. We studied 103 cases of endometrioid endometrial carcinoma using immunohistochemistry. We correlated the findings with various clinicopathological parameters of the patients. PRA and PRB immunoreactivity was detected in 51/103 (48.5%) and 79/103 (76.7%) of carcinoma cases, respectively. A significant positive correlation was detected between the status of PRB immunoreactivity and the amount of PRB mRNA by real-time reverse transcription-polymerase chain reaction (P = 0.012). PR isoform expression was significantly lower in the cases with higher histological grade (P = 0.0001 and P = 0.002, for PRA and PRB, respectively). Cases that were negative for either one or both PR isoforms were significantly associated with shorter disease-free and overall survival of the patients. The absence of either one or both of these two PR isoforms was detected in all nine patients who died (100.0%), whereas the absence of these immunoreactivities was detected only in 43 of 94 (45.7%) patients who had lived during the same period. In addition, multivariate analysis demonstrated that an absence of PRA immunoreactivity was an independent risk factor in disease-free survival of the patients (P = 0.0258). The results of our study demonstrated that loss or absence of PR isoform expression determined by immunohistochemistry could become an important prognostic indicator in patients with endometrioid endometrial carcinoma.